Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background & Aims: Primary biliary cholangitis (PBC) can result in life‐altering cholestatic pruritus and fatigue, but treatment options are limited. Seladelpar, a peroxisome proliferator‐activated receptor‐delta (PPARδ) agonist, has demonstrated potent anti‐cholestatic effects in clinical studies. This open‐label, uncontrolled phase 2 study in PBC patients evaluated the effects of 1‐year of seladelpar treatment on measures of pruritus and quality of life. Methods: Self‐reported experiences of 101 PBC patients were collected at baseline and after 1 year of seladelpar treatment using the pruritus visual analog scale (VAS), 5D‐itch scale, and PBC‐40 questionnaires along with bile acid profiles. Results: In patients with moderate–to‐severe pruritus, substantial improvement in pruritus was seen in 58% and 93% of patients in 5/10 mg and 10 mg treatment groups, respectively. After 1 year, patients reporting improvement substantially outnumbered those who worsened in the total 5‐D itch (including individual domains) and PBC‐40 (itch and fatigue domains) questionnaires. Improvement in sleep disturbance at 1‐year was reported in 81% (5/10 mg) and 78% (10 mg) of the patients with baseline itch‐related sleep disturbance by 5‐D itch score with similar results using the PBC‐40 sleep questionnaire. Seladelpar‐treated patients had significant reductions of 46% (5/10 mg) and 31% (10 mg) in the serum bile acid precursor C4 and reductions of up to 38% in serum bile acids. Conclusions: Seladelpar treatment for 1 year led to consistent improvement in both symptom burden and biochemical response, suggesting its potential as a single agent to address two key unmet needs in PBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“Pruritus VAS (0100) VAS ≥40 VAS <40 23 [24] 59 [15] 11 [11] 30 [28] 65 [17] 13 [14]”
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Self-citationPrimary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Self-citationLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Self-citationPruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225
Self-citationde Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.001 · Cited by 224
Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30319-7 · Cited by 206
Self-citation
Research works printed but not linked: 28
- Galoosian A, 2020, Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches, J Clin Transl Hepatol, 8, 49
- 10.1002/cld.867 · DOI
- 10.1053/bega.2000.0109 · DOI
- 10.1002/hep.29698 · DOI
- 10.1007/s11901-020-00517-x · DOI
- 10.1016/j.amjmed.2017.01.037 · DOI
- 10.1136/flgastro-2015-100618 · DOI · Paper page
- 10.1007/s10620-019-05786-1 · DOI
- 10.1007/s11901-019-00458-0 · DOI
- 10.1111/liv.13919 · DOI · Paper page
- 10.1016/j.jhep.2013.02.019 · DOI · Paper page
- 10.1016/S2468-1253(17)30246-7 · DOI · Paper page
- 10.1016/S0168-8278(20)31411-2 · doi:10.1016/s0168-8278(20)31411-2
- 10.1111/j.1365-2133.2009.09586.x · DOI · Paper page
- 10.1136/gut.2005.065862 · DOI · Paper page
- 10.2340/00015555-1265 · DOI · Paper page
- 10.2340/00015555-2433 · DOI
- 10.1111/j.1572-0241.2006.00423.x · DOI
- Bowlus C, 2018, Efficacy and safety of seladelpar, a selective peroxisome proliferator activated receptor delta agonist, in primary biliary cholangitis: 52‐week analysis of an ongoing international, randomized, dose ranging phase 2 study, Hepatology, 68, 1445A
- Boudes P, 2018, Seladelpar’s mechanism of action as a potential treatment for primary biliary cholangitis and non‐alcoholic steatohepatitis, J Hepatol, 68, S235, 10.1016/S0168-8278(18)30688-3 · doi:10.1016/s0168-8278(18)30688-3
- 10.1210/jc.2011-1061 · DOI · Paper page
- 10.1007/s11894-019-0713-6 · DOI
- 10.1002/hep.21271 · DOI · Paper page
- 10.1111/apt.13449 · DOI · Paper page
- 10.1073/pnas.1903316116 · DOI · Paper page
- 10.7554/eLife.48431 · DOI · Paper page
- Wolf K, 2019, Bile salt subspecies activate MRGX4 expressed on sensory neurons and cause itching in humans, Hepatology, 70, 769A
- 10.1038/srep30847 · DOI
Cited by
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Self-citationPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Self-citationHirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
“Improvement in pruritus has been previously observed with treatment with seladelpar 10 mg QD through 1 year.[20] Pruritus is a significant burden for patients with PBC that is often undertreated,[28–30] suggesting that seladelpar has the potential to add this benefit to that of improving biomarkers associated with dis…”
BackgroundMethodInfluentialSelf-citationInvernizzi, P., Carbone, M., Jones, D., Levy, C., Little, N., Wiesel, P., Nevens, F., & the study investigators (2023) · Liver International · doi:10.1111/liv.15596 · Cited by 79
Self-citationMayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39
“35,41 The objectives of this current study were to evaluate the long-term safety, tolerability and efficacy of seladelpar at 5 and 10 mg once daily during the long-term extension of treatment.”
BackgroundSelf-citation
Metadata
- Authors
- Kremer, A. E., Mayo, M. J., Hirschfield, G., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A., McWherter, C. A., & Choi, Y.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2021-08-26
- Volume
- 42
- Issue
- 1
- Pages
- 112-123
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3193674176
- Cited by
- 89
- References
- 14
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. https://app.cochat.ai/papers/10.1111/liv.15039
- The paper
- Kremer, A. E., Mayo, M. J., Hirschfield, G., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A., McWherter, C. A., & Choi, Y. (2022). Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International. https://doi.org/10.1111/liv.15039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.